Synergistic effects of LFchimera and antibiotic against planktonic and biofilm form of Aggregatibacter actinomycetemcomitans.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
04
2019
accepted:
07
05
2019
entrez:
23
7
2019
pubmed:
23
7
2019
medline:
18
2
2020
Statut:
epublish
Résumé
Adjunctive use of antibiotics in periodontal treatment have limitations and disadvantages including bacterial resistance. Antimicrobial peptides (AMPs) are potential new agents that can combat bacterial infection. In this study, antimicrobial activity of different concentrations of conventional antibiotics minocycline (MH), doxycycline (DOX), and antimicrobial peptides LL-37, LL-31, Lactoferrin chimera (LFchimera) and Innate Defense Regulator Peptide 1018 (IDR-1018) against Aggregatibacter actinomycetemcomitans ATCC 43718 were determined using colony culturing assay. Subsequently, in vitro activity of the most effective drug and peptide combination was evaluated by checkerboard technique. Impact of the drug and peptide co-administration on biofilm at different stages, i.e., during adhesion and 1-day old biofilm was compared to each of the agents used alone. Results revealed that the killing effects of all AMPs range from 13-100%. In contrast, MH and DOX at 1 and 5 μM showed no killing activity and instead stimulated growth of bacteria. DOX has better killing activity than MH. LFchimera displayed the strongest killing amongst the peptides. Checkerboard technique revealed that combining DOX and LFchimera yielded synergism. Confocal laser scanning microscopy further showed that the combination of DOX and LFchimera caused significant reduction of bacterial adhesion and reduction of biomass, average biofilm thickness and substratum biofilm coverage of 1-day old biofilm compared to DOX and LFchimera alone. In conclusion, LFchimera alone and in combination with DOX exhibited strong antibacterial and anti-biofilm property against A. actinomycetemcomitans. The findings suggest that LFchimera should be considered for development as a new potential therapeutic agent that may be used as an adjunctive treatment for periodontitis.
Identifiants
pubmed: 31329599
doi: 10.1371/journal.pone.0217205
pii: PONE-D-19-10261
pmc: PMC6645458
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimicrobial Cationic Peptides
0
LTF protein, human
0
Recombinant Fusion Proteins
0
innate defense regulating peptide 1018
0
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0217205Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Dent Hyg. 2013 Oct;87(5):249-64
pubmed: 24158658
Biochem Cell Biol. 2012 Jun;90(3):378-88
pubmed: 22364313
Biometals. 2014 Oct;27(5):949-56
pubmed: 24961697
J Periodontol. 1971 Aug;42(8):516-20
pubmed: 5284178
Antimicrob Agents Chemother. 2012 Nov;56(11):5698-708
pubmed: 22908164
J Antimicrob Chemother. 2003 Jul;52(1):1
pubmed: 12805255
J Periodontol. 2004 Apr;75(4):592-9
pubmed: 15152825
J Periodontal Res. 2010 Aug;45(4):557-63
pubmed: 20546113
Res Microbiol. 2012 Feb;163(2):101-8
pubmed: 22172555
Biochimie. 2009 Jan;91(1):123-32
pubmed: 18573310
Oral Microbiol Immunol. 1995 Aug;10(4):227-32
pubmed: 8602335
Res Microbiol. 2012 Jul;163(6-7):479-86
pubmed: 22705395
Lett Appl Microbiol. 2013 Dec;57(6):467-75
pubmed: 23848166
Int J Oral Sci. 2011 Apr;3(2):66-73
pubmed: 21485310
J Periodontol. 2014 Jan;85(1):160-9
pubmed: 23688097
Ann Periodontol. 2003 Dec;8(1):79-98
pubmed: 14971250
Antimicrob Agents Chemother. 2014 Oct;58(10):5719-25
pubmed: 25022581
Appl Environ Microbiol. 2009 Feb;75(3):837-41
pubmed: 19028906
World J Microbiol Biotechnol. 2016 Feb;32(2):33
pubmed: 26754671
Int J Antimicrob Agents. 2010 Nov;36(5):447-52
pubmed: 20685090
Biochimie. 2009 Jan;91(1):133-40
pubmed: 18625283
J Antimicrob Chemother. 2006 Jul;58(1):198-201
pubmed: 16687459
World J Microbiol Biotechnol. 2013 Jul;29(7):1217-24
pubmed: 23404819
Int J Antimicrob Agents. 2012 Jan;39(1):39-44
pubmed: 22005071
PLoS Pathog. 2010 Oct 28;6(10):e1001067
pubmed: 21060861
Caries Res. 2010;44(4):372-9
pubmed: 20668379
Chem Biol. 2010 Sep 24;17(9):970-80
pubmed: 20851346
J Clin Periodontol. 1997 Apr;24(4):254-9
pubmed: 9144048
J Periodontol. 2005 Dec;76(12):2187-93
pubmed: 16332229
World J Microbiol Biotechnol. 2017 Aug 19;33(9):167
pubmed: 28823045
J Oral Microbiol. 2013 May 08;5:
pubmed: 23671757
Biometals. 2010 Jun;23(3):569-78
pubmed: 20195887
Microbiology. 2000 Oct;146 ( Pt 10):2395-2407
pubmed: 11021916
PLoS Pathog. 2014 May 22;10(5):e1004152
pubmed: 24852171
J Pharm Bioallied Sci. 2012 Aug;4(Suppl 2):S252-5
pubmed: 23066264
Biochim Biophys Acta. 2006 Sep;1758(9):1408-25
pubmed: 16716248
Periodontol 2000. 1994 Jun;5:142-68
pubmed: 9673166
Periodontol 2000. 2002;28:298-312
pubmed: 12013347
Periodontol 2000. 1999 Jun;20:82-121
pubmed: 10522224
Amino Acids. 2012 Dec;43(6):2265-77
pubmed: 22543751
J Clin Microbiol. 2007 Dec;45(12):3859-69
pubmed: 17942658
Cell Immunol. 2012 Nov;280(1):22-35
pubmed: 23246832
Ann Periodontol. 1996 Nov;1(1):879-925
pubmed: 9118283
Arch Mikrobiol. 1971;75(4):374-81
pubmed: 4927242